Daniel J. Brennan - Feb 22, 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP and CFO
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Feb 22, 2022
Transactions value $
-$1,501,870
Form type
4
Date filed
2/24/2022, 03:18 PM
Previous filing
Feb 23, 2022
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $291K +16.9K +6.18% $17.26 290K Feb 22, 2022 Direct F1
transaction BSX Common Stock Options Exercise $246K +15.1K +5.21% $16.31 305K Feb 22, 2022 Direct F1
transaction BSX Common Stock Options Exercise $179K +13.7K +4.48% $13.08 318K Feb 22, 2022 Direct F1
transaction BSX Common Stock Options Exercise $56K +7.57K +2.38% $7.39* 326K Feb 22, 2022 Direct F1
transaction BSX Common Stock Sale -$2.27M -53.2K -16.31% $42.75 273K Feb 22, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Performance Share Units Award $0 +24K $0.00 24K Feb 22, 2022 Common Stock 24K Direct F3, F4
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -16.9K -25% $0.00 50.6K Feb 22, 2022 Common Stock 16.9K $17.26 Direct F1, F5
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -15.1K -25% $0.00 45.3K Feb 22, 2022 Common Stock 15.1K $16.31 Direct F1, F6
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -13.7K -33.33% $0.00 27.3K Feb 22, 2022 Common Stock 13.7K $13.08 Direct F1, F7
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -7.57K -50% $0.00 7.57K Feb 22, 2022 Common Stock 7.57K $7.39 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F2 Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $42.48 to $43.08, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3 Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4 On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023.
F5 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F6 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
F7 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.
F8 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.